Wizemann, Theresa, Robinson, Sally, Giffin, Robert. "Appendix B: Speaker Biographies." Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press, 2008.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies - Workshop Summary
she managed a programmatic portfolio on HIV/AIDS and other sexually transmitted diseases, infectious diseases, women’s health, and public health infrastructure issues. From 1987 to 1991, she was an Analyst and Project Director at the Congressional Office of Technology Assessment. Ms. Anderson currently serves as a member of the Whitman-Walker Clinic Institutional Review Board and has held numerous committee and coalition memberships for federal agencies and professional associations in the biomedical and public health arena. She holds a bachelor’s degree from the University of Maryland and a master’s degree in science, technology, and public policy from The George Washington University’s Elliott School of International Affairs.
Mark L. Batshaw, M.D., is the “Fight for Children” Chair of Academic Medicine and Chief Academic Officer at the Children’s National Medical Center (CNMC) in Washington, DC, and Professor and Chairman of Pediatrics and Associate Dean for Academic Affairs at The George Washington University School of Medicine and Health Sciences, also in Washington, DC. Dr. Batshaw is a graduate of the University of Pennsylvania and the University of Chicago Pritzker School of Medicine. Following pediatric residency at the Hospital for Sick Children in Toronto, he completed a fellowship in developmental pediatrics at the the Johns Hopkins Medical Institutions. Dr. Batshaw is Director of the National Institutes of Health (NIH)–funded Rare Diseases Clinical Research Center at CNMC and continues to pursue his research on innovative treatments for inborn errors of metabolism, including gene therapy. He has published more than 150 articles, chapters, and reviews on his research interests and on the medical aspects of the care of children with disabilities.
Enriqueta C. Bond, Ph.D., is President of the Burroughs Wellcome Fund. She received her undergraduate degree from Wellesley College, her M.A. from the University of Virginia, and her Ph.D. in molecular biology and biochemical genetics from Georgetown University. She is a member of the Institute of Medicine (IOM), the American Association for the Advancement of Science, the American Society for Microbiology, and the APHA. Dr. Bond chairs the National Academies’ Board on Capacity Development of African Academies of Science and serves on the Report Review Committee for the National Academies. She serves on the board and executive committee of the Research Triangle Park Foundation, on the board of the National Institute for Statistical Sciences, on the board of the Northeast Biodefense Center and the New England Center of Excellence in Biodefense and Emerging Infectious Diseases, and on the council of the National Institute of Child Health and Human Development. Prior to being named President of the Burroughs Wellcome Fund in 1994,